Skip to content
10-Q

Quarterly Report

GALECTIN THERAPEUTICS INC GALT

0001140361-25-019149

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 7, 2025 63.29M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $7.43M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $15.12M
Current Liabilities Q1 2025 · Mar 31, 2025 $110.84M
Current Liabilities Q1 2025 · Dec 31, 2024 $35.41M
Total Liabilities Q1 2025 · Mar 31, 2025 $121.79M
Total Liabilities Q1 2025 · Dec 31, 2024 $120.57M
Current Assets Q1 2025 · Mar 31, 2025 $9.29M
Current Assets Q1 2025 · Dec 31, 2024 $17.25M
Total Assets Q1 2025 · Mar 31, 2025 $9.53M
Total Assets Q1 2025 · Dec 31, 2024 $17.5M
Shares Diluted Q1 2025 · Mar 31, 2024 61.98M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$12.11M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$72.81M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$61.96M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.19
Eps Basic Q1 2025 · Mar 31, 2024 −$0.19
Sga Expense Q1 2025 · Mar 31, 2024 $1.59M
Rd Expense Q1 2025 · Mar 31, 2024 $8.05M
Net Income Q1 2025 · Mar 31, 2024 −$11.49M
Operating Income Q1 2025 · Mar 31, 2024 −$9.65M